ICON Names New Global Head of Clinical Research Services
01 Novembro 2011 - 9:00AM
Business Wire
ICON plc.(NASDAQ:ICLR)(ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
Dr. Steve Cutler will join the company as Group President, Clinical
Research Services.
Dr. Cutler has over 23 years’ experience within the
pharmaceutical and CRO industry and joins ICON from Kendle where he
held the position of Chief Executive Officer, having previously
served as Kendle’s Chief Operating Officer. Prior to Kendle, Dr.
Cutler spent 14 years with Quintiles where he served as Senior Vice
President, Global Project Management; Senior Vice President,
Clinical, Medical and Regulatory; Senior Vice President, Project
Management - Europe; and Vice President, Oncology - Europe as well
as regional leadership positions in South Africa and Australia.
Prior to joining Quintiles Dr. Cutler held positions with Sandoz
(now Novartis) in Australia and Europe. He holds a B.Sc. and a PhD
from the University of Sydney and a Masters of Business
Administration from the University of Birmingham (UK).
ICON also announced that Mr Alan Morgan, the former Group
President, Clinical Research Services, has resigned from his
position and will leave the organisation at the end of April 2012
to pursue other opportunities.
Commenting on the organisational changes, Ciaran Murray CEO of
ICON said “We are delighted to welcome Steve to ICON. He is joining
us at a time when we are building the foundations for long-term
sustainable growth and his experience and proven leadership
capabilities will be important as we continue to enhance our
position as the global CRO partner of choice for the Biopharma
industry. I would also like to thank Alan for his commitment to
ICON and acknowledge the contribution he has made to our
organisation. I wish him every success in the future.”
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has around 8300 employees, operating from 79 locations in 38
countries.
Further information is available at www.iconplc.com
DISCLOSURE NOTICE: The statements made in this press
release may contain forward-looking statements that involve a
number of risks and uncertainties. In addition to the matters
described in this press release, the ability to maintain large
client contracts or enter into new contracts, maintain client
relationships and the ability to manage the opening of new offices,
the integration of new business mergers and acquisitions, as well
as other risks and uncertainties detailed from time to time in SEC
reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3,
may affect the actual results achieved by ICON. ICON disclaims any
intent or obligation to update these forward-looking
statements.
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024